Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: Design and rationale of the AQUA-TLV study

International Heart Journal

Volumn 55, Issue 3, 2014, Pages 264-267

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Ohtani, Tomohito ^b   Sakata, Yasushi ^b   Higo, Taiki ^c   Kinugawa, Shintaro ^d   Tsutsui, Hiroyuki ^d   Sunagawa, Kenji ^c   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Responder; Urine osmolality; Vasopressin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; DIURETIC AGENT; FUROSEMIDE; POTASSIUM; SODIUM; TOLVAPTAN;

ARTICLE; CARDIOMEGALY; CLINICAL ASSESSMENT; CONTROLLED STUDY; HEART FAILURE; HEPATOMEGALY; HOSPITALIZATION; HUMAN; LONG TERM CARE; LUNG CONGESTION; MAJOR CLINICAL STUDY; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REFRACTORY HEART FAILURE; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; URINE OSMOLALITY;

AGED; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECEPTORS, VASOPRESSIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901498303     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-326     Document Type: Article

References (30)

1. Kinugawa K. How to treat stage D heart failure?-When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038-2045. (Review)
2. Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant 2004; 23: 1082-6
3. Kato N, Kinugawa K, Seki S, et al. Quality of life as an independent predictor for cardiac events and death in patients with heart failure. Circ J 2011; 75: 1661-9
4. Garin O, Ferrer M, Pont A, et al. Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res 2009; 18: 71-85. (Review)
5. Michael Felker G. Diuretic management in heart failure. Congest Heart Fail 2010; 16: S68-S72. (Review)
6. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994; 128: 564-574. (Review)
7. Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med 2006; 73: S4-S12. (Review)
8. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293: 572-580
9. Shiba N, Watanabe J, Shinozaki T, et al. Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. Circ J 2004; 68: 427-434
10. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 2006; 70: 1617-1623
11. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013; 61: 169-174
12. Watanabe K, Dohi K, Sugimoto T, et al. Short-term effects of lowdose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012; 60: 462-9
13. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331
14. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-5
15. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112
16. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404
17. Imamura T, Kinugawa K, Shiga T, et al. Correction of hyponatremia by tolvaptan before left ventricular assist device implantation. Int Heart J 2012; 53: 391-3
18. Imamura T, Kinugawa K, Minatsuki S, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 2013; 77: 1208-1213
19. Imamura T, Kinugawa K, Kato N, et al. Successful conversion from thiazide to tolvaptan in a patient with stage d heart failure and chronic kidney disease before heart transplantation. Int Heart J 2013; 54: 48-50
20. Imamura T, Kinugawa K, Minatsuki S, et al. Tolvaptan can improve clinical course in responders. Int Heart J 2013; 54: 377-381
21. Kinugawa K, Imamura T, Komuro I. Experience of a vasopressin receptor antagonist, tolvaptan under the unique indication in Japanese heart failure patients. Clin Pharmacol Ther 2013; 94: 449-451
22. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011; 7: 151-61. (Review)
23. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25: S57-S65
24. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-6
25. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure associa tion of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010; 12: 423-433. (Review)
26. Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 2010; 160: 264-271. e1
27. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759-1764
28. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007; 28: 980-8
29. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007; 167: 1998-2005
30. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009; 122: 857-865.